Title

Basic Information
Predicted Impact on Human Body
Basic Information
BGC Name(-)-delta-cadinene biosynthetic gene cluster
MicrobeStreptomyces clavuligerus ATCC 27064
Metabolite(-)-delta-cadinene
Predicted Impact on Human Body
Side Effect
NameScore
Blister 0.5000
Skin mass 0.5000
Pseudolymphoma 0.5000
Hepatic failure 0.4318
Skin hypertrophy 0.3632
Breast tenderness 0.3826
Carpal tunnel syndrome 0.3808
Application site burn 0.3653
Allergic contact dermatitis 0.5000
Skin nodule 0.5000
Potential Indication
DescriptionScore
Methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.0.5278
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.0.5455
For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.0.5172
For progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.0.5938
For the treatment of severe recalcitrant nodular acne0.5172
For the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.0.6129
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).0.5588
For the treatment of vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.0.5429
For topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.0.5172
Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.0.5938
Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).0.5758
Impact on Immune System
Immune Status TransitionCellTissuep valueScore
DC.8+.SLN-DC.8+.ThDCsdLN1e-150.2818
Tgd.vg2+.Sp-Tgd.vg2-.SpTgdspleen1e-170.2850
T.8Eff.Sp.OT1.d5.VSVOva-T.8Eff.Sp.OT1.d6.VSVOvaT8spleen1e-170.2947
Tgd.vg2+.Sp-Tgd.vg2-.SpTgdspleen1e-170.2850
T.8Nve.MLN-T.8Nve.SpT8spleen1e-150.3279
T.8Eff.Sp.OT1.d6.LisOva-T.8Eff.Sp.OT1.d8.LisOvaT8spleen1e-150.2773
T.8Nve.MLN-T.8Nve.SpT8spleen1.07467e-170.2757
T.8Nve.LN-T.8Nve.SpT8spleen1e-150.3064
T.8Eff.Sp.OT1.d5.VSVOva-T.8Eff.Sp.OT1.d6.VSVOvaT8spleen1e-150.3446
Tgd.vg1+vd6+.Th.TCRbko-Tgd.vg1+vd6+24ahi.Th.TCRbkoTgdthymus1e-150.3090